Endpoints News
Industry Snippets: Scoop: SR One crew completes a complicated spinout from GlaxoSmithKline. And now they have a $500M fund to invest on their own
Endpoints News

It’s taken close to 2 years, but Simeon George and his team at SR One have completed their spinout from GlaxoSmithKline, ending a saga as one of the longest running venture arms of Big Pharma as they go out on their own to forge the next chapter with a new and independent $500 million fund.

GSK is sticking with the spinout, this time as a minority investor — though a big one.

Need to be a subsriber to read the full article.